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Background: The aim of this study was to examine the efficacy and safety of everolimus in patients with progressive
unresectable adenoid cystic carcinoma (ACC).
Methods: Histologically confirmed ACC patients with documented disease progression within 12 months prior to
the study entry were eligible. Everolimus was given at a dose of 10 mg daily until progression or occurrence of
unacceptable toxicities. The primary endpoint was a 4-month progression-free survival (PFS).
Results: A total of 34 patients were enrolled. The 4-month PFS probability was 65.5% (95% one-sided confidence
interval [CI], 47.7 to infinity). Median PFS duration was 11.2 months (95% CI, 3.6 to 15.8). Complete or partial response
was not achieved. Twenty-seven (79.4%, 95% CI, 63.2 to 89.6) patients showed stable disease (SD). Tumor shrinkage
within SD criteria was observed in 15 patients (44.1%) and SD lasting 6 months was observed in 13 patients (38.2%).
Four patients had disease progression. Among the 18 patients with both pre- and post-treatment (at 8 weeks) FDG-PET
scans available, 8 patients (44.4%) showed a partial metabolic response, defined as a ≥25% reduction in maximum
standardized uptake values (SUVmax). The most common adverse events were stomatitis, anemia, asthenia, and
leukopenia. No unexpected everolimus related toxicities were reported.
Conclusions: Everolimus showed promising efficacy and good tolerability in progressive unresectable ACC.
Trial registration: ClinicalTrials.gov identifier, NCT01152840
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Adenoid cystic carcinoma (ACC) is a rare epithelial malig-
nancy that arises in secretory glands, particularly in the
salivary glands. Although the histologic appearance of
ACC is low grade, management of this malignancy is a
distinct therapeutic challenge because of its tendency for
perineural involvement and potential for distant meta-
stasis [1]. The natural course of metastatic disease is rela-
tively indolent; however, most patients with metastatic
disease ultimately die from their cancer [2]. Therefore, a* Correspondence: bangyj@snu.ac.kr
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unless otherwise stated.more effective treatment strategy for unresectable disease
is definitely required.
Cytotoxic chemotherapies have been evaluated for
advanced ACC in a numbers of clinical trials of. A sys-
tematic review of systemic therapy for advanced ACC
reported that objective responses to any cytotoxic agent
or regimen were very infrequent, whereas stabilization
of disease was observed more commonly [3]. Rates of
disease stabilization need to be interpreted with caution
in an indolent cancer; however, disease stabilization may
be only a marker of antitumor activity. Assessment of
disease stabilization is more useful if disease progression
is documented before the study entry.
Recently, a series of targeted agents were tested for
the treatment of advanced ACC. However, no study has
focused on the phosphatidylinositol 3-kinase (PI3K)-Akt-. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ACC. According to the Younes et al. [4], ACC cell lines
exhibited increased phosphorylated Akt activity when stim-
ulated with epidermal growth factor (EGF). And, when
treated with epidermal growth factor receptor (EGFR)/vas-
cular endothelial growth factor receptor (VEGFR) tyrosine
kinase dual inhibitor, the phosphorylated form of Akt
decreased even though the total level of Akt is remained
unchanged. Of note, an ACC patient had clinical response
to everolimus in a phase I study [5]. Therefore, we perfor-
med this phase II study to evaluate the efficacy of everoli-
mus in advanced ACC. We required documented evidence
of disease progression to exclude those patients with stable
disease due to intrinsically slow growth rate.
Methods
This open-label, multicenter, phase II, single arm study
(ClinicalTrials.gov identifier, NCT01152840) was conduc-
ted at 9 hospitals in Korea. The study was conducted in
compliance with Good Clinical Practice, guidelines of
the International Conference on Harmonisation, and the
Declaration of Helsinki, and approved by the local institu-
tional review boards (IRBs) of Seoul National University
Hospital, Kosin University Gospel Hospital, Catholic
University Seoul St. Mary’s Hospital, Yonsei Cancer
Center, Pusan National University Hospital, Seoul Veterans
Hospital, Keimyung University Dongsan Hospital, Hallym
University Medical Center, and National Cancer Center in
Korea. Written informed consent was required from all
patients before participation.
Study population
Adult patients with histological evidence of advanced or
metastatic adenoid cystic carcinoma were eligible for this
study. Evidence of disease progression according to the
Response Evaluation Criteria in Solid Tumors (RECIST)
criteria (version 1.0) [6] must be documented by CT or
MRI scans taken within 12 months prior to the baseline
evaluation and compared to a previous scan taken at any
time in the past. Previous treatment with chemotherapy,
radiation therapy or surgery were permitted providing
that toxicity had resolved to ≤ grade 1 at study entry and
that last treatment was at least 4 weeks prior to baseline
assessment. Patients were required to have measurable
lesions according to the RECIST criteria (version 1.0),
a WHO performance status of 0-1 [7], and adequate
hematologic, renal, and hepatic function. Patients with
previous active or passive immunotherapy, intestinal
obstruction or impending obstruction, recent active
upper gastrointestinal bleeding, history of another malig-
nant disease within the past 5 years (except for curatively
treated basal cell carcinoma of skin and cervical carcin-
oma in situ), medically uncontrolled systemic disease,
interstitial pneumonia or diffuse symptomatic pulmonaryfibrosis were not eligible. Pregnant or lactating women
were excluded.
Treatment and evaluation
Patients received 10 mg of daily oral everolimus and one
cycle was comprised of 28 days. Treatment was con-
tinued until disease progression, unacceptable toxicity,
or consent withdrawal. Concomitant anticancer agents
other than everolimus were not allowed during the
study. Response, based on RECIST criteria (version 1.0),
was evaluated every 8 weeks until progression was obser-
ved, and survival status was assessed every 12 weeks
after the end of treatment visit. Metabolic response
was assessed by 18F-fluorodeoxyglucose (FDG) positron
emission tomography (PET) scan in selected cases. FDG-
PET scan was performed at screening and at 8 weeks of
treatment. Metabolic response was evaluated as described
in a previous study [8]. Briefly, a metabolic CR was de-
fined as a complete resolution of FDG uptake within the
tumor so that it was indistinguishable from surrounding
normal tissue. A metabolic PR was defined as a reduction
of ≥25% in tumor maximum standardized uptake values
(SUVs) of FDG uptake. An ≥25% increase in tumor max-
imum SUVs or the appearance of new FDG uptake in
another region was defined as metabolic progressive dis-
ease (PD). Metabolic stable disease (SD) was defined
as an increased in the tumor SUV of <25% or a decrease
of <25%. Safety assessments, including history taking,
physical examination, and laboratory evaluation, were car-
ried out at baseline and at the end of each cycle. Adverse
events was monitored and recorded according to the
National Cancer Institute Common Terminology Criteria
for Adverse Events (NCI-CTCAE) version 3.0 during the
treatment phase and for 28 days after the final dose of
the study medications. Only serious adverse events were
reported during the 28 days after the final dose of the
study medications in the post-study treatment phase.
Dose modifications or delays in study drug administra-
tion were allowed as per protocol. When the study
medication was delayed, all the evaluations, including
tumor evaluation, adhered to the original schedule. Rea-
sons for changes in dose or delays in administration, mea-
sures and outcome were recorded in the case report form.
The patient was considered to be an early drop-out due to
toxicity if administration of study medications was either
delayed for ≥3 weeks or discontinued due to toxicity.
Statistical methods
The primary efficacy end point was progression-free sur-
vival (PFS) at 4 months. Patients who received at least
one dose of everolimus were included in the intent-to-
treat (ITT) population. All efficacy and safety analyses
were performed on the ITT population. The hypoth-
esis of this study was that the 4-month PFS rate would
Table 1 Baseline characteristics of patients (intention-to-





Gender – N (%)
Male 18 (52.9)
Female 16 (47.1)
Duration of disease - year
(from initial diagnosis to study enrollment)
Median (Mean) 4.4 (6.0)
Range 0.5-22.0
Primary site – N (%)
Salivary gland 13 (38.2)
Paranasal sinus 8 (23.5)
Oral cavity/oropharynx 6 (17.6)
Nasal cavity/nasopharynx 2 (5.9)
Larynx 2 (5.9)
Lung 1 (2.9)
Bartholin gland 1 (2.9)
Unknown 1 (2.9)
Site of metastasis – N (%)
Lung 32 (94.1)
Bone 8 (23.5)
Non-regional lymph nodes 5 (14.7)
Liver 3 (8.8)
Soft tissue 3 (8.8)
Pleura 2 (5.9)
Kidney 2 (5.9)
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tients to test the null hypothesis that the true proportion
of patients who remained progression-free at 4 months
from study entry is at most 50%, with 80% power to detect
a 4-months PFS proportion of 65%, with a one-sided
hypothesis test and an Type I error of 0.05. This sample
size was based on the assumptions that patient survival
followed an exponential distribution and that no patients
would be lost to follow-up. Assuming a dropout rate of
15%, the required number of patients was 33. The second-
ary endpoints included objective response rate, disease
control rate, duration of responses, and length of overall
survival (OS) after initiation of the study medication. The
median PFS and OS and their confidence intervals (CIs)
were calculated using Kaplan-Meier method [9]. P-value
for the one-sided hypothesis test was calculated using a
normal distribution approximation of the survival rate
with its standard error. The frequency and severity of
adverse events (AEs) were analyzed. Statistical analysis
was conducted using STATA version 12.0 (StataCorp LP,
College Station, TX, USA).
Results
Patients
From July 2008 through October 2010, 34 patients were
enrolled. All those patients received at least one dose of
everolimus (ITT population) and were included in the
efficacy and safety analyses. The patients’ baseline char-
acteristics are summarized in Table 1. The salivary gland
was the most common primary site, and the other primary
sites included the paranasal sinus, oral cavity, nasal cavity,
larynx, lung, and the Bartholin gland. The median interval
from initial diagnosis of ACC to initiation of study treat-
ment was 4.4 years. The most common metastatic site
was lung. At the censoring date (Mar 25, 2013), 20
progression events and 20 deaths had occurred, and
the median length of follow-up was 19.8 months (range
2.5 to 54.2).
Efficacy
The 4-months PFS probability was 65.5% (95% one-
sided CI, 47.7 to infinity) but did not differ significantly
from the null hypothesis of a 4-months PFS rate ≤50%
(P = 0.076). Median PFS duration was 11.2 months (95%
CI, 3.6 to15.8) (Figure 1). No patient achieved CR or PR.
Twenty-seven (79.4%) patients had SD (95% CI, 63.2 to
89.6). Tumor shrinkage within the SD criteria was ob-
served in 15 (44.1%) patients (Figure 2) and SD >6 months
was observed in 13 patients. Four patients had PD
(Table 2). Pre-treatment and post-treatment (after 8 weeks)
FDG-PET scan was available for 18 patients. All these 18
patients had SD based on RECIST criteria. Among
them, the scans indicated metabolic PR in 8 patients,
metabolic SD in 9 patients, and metabolic PD in onepatient (Figure 3). The median PFS duration of the 8 pa-
tients with metabolic PR was numerically longer than that
that of the 10 patients with metabolic SD or PD (15.1
versus 3.8 months). The median OS was 23.7 months
(95% CI, 6.8 to 40.6).
Safety
Mean treatment duration was 7.5 months (range, 0.4 to
37.7). No patient discontinued treatment due to AEs.
The most common AEs were stomatitis, anemia, and
asthenia. The major Grade 3 and 4 AEs were asthenia
Figure 1 Progression free survival (intention-to-treat population, N = 34).
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dose of everolimus was adjusted for 8 patients (24%). No
unexpected toxicities of everolimus were observed.
Discussion
To the best of our knowledge, this study is the largest
clinical trial of systemic treatment of advanced ACC.
Although the primary hypothesis of this study was not
fulfilled, everolimus had clinical efficacy in patients with
ACC who all had disease progression before treatment.Figure 2 Best percent changes in tumor size by patients (response evThe median PFS duration was 11.2 months, 79.4% of
patients achieved SD, and tumor shrinkage within SD
criteria was observed in 44% of patients. Furthermore,
pre- and post-treatment FDG-PET scans indicated a
metabolic PR in 8 (44.4%) out of 18 evaluated patients.
Interestingly, the length of PFS of the 8 patients with
metabolic PR was longer than that of the other 10
patients with metabolic SD/PD. This survival difference
suggests that an early metabolic response may be pre-
dictive of durable response.aluable patients, N = 31).
Table 2 Best overall responses (N = 34, intention-to-treat
population)
Response, N (%)
Complete Response (CR) 0 (0.0)
Partial Response (PR) 0 (0.0)
Stable Disease (SD) 27 (79.4)
Progressive Disease (PD) 4 (11.8)
Not evaluable 3 (8.8)
Objective response rate (CR + PR)% 0.0
Disease control rate (CR + PR + SD)% 79.4
Table 3 Adverse events of any cause (reported in 10% or
more of patients, N = 34)
Adverse events All grades, N (%) Grade 3 or 4, N (%)
Stomatitis 27 (79.4) 1 (2.9)
Anemia 22 (64.7) 1 (2.9)
Asthenia 13 (38.2) 2 (5.9)
Leukopenia 11 (32.4) 1 (2.9)
Neutropenia 10 (29.4) 0 (0.0)
Rash 10 (29.4) 0 (0.0)
Infection 8 (23.5) 2 (5.9)
Nausea 5 (14.7) 0 (0.0)
Dyspnea 5 (14.7) 0 (0.0)
Anorexia 5 (14.7) 0 (0.0)
Thrombocytopenia 4 (11.8) 0 (0.0)
Epistaxis 4 (11.8) 0 (0.0)
Cough 4 (11.8) 0 (0.0)
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is more evident when it is compared with the efficacy of
other molecular targeted agents reported in previous clin-
ical trials. Because c-kit is expressed in a high proportion
of ACCs [10,11], imatinib, a c-kit tyrosine kinase inhibitor,
was of potential interest. Two phase II studies examined
the efficacy of imatinib in patients with ACC that had
immunohistochemical evidence of c-kit expression [12,13].
There was no objective response in the either study. In one
study, SD was observed in 60% (9 of 15) of the patients,
but median PFS duration was only 10 weeks [12]. The
other study reported only 2 patients with SD among the 10
ACC patients [13]. Lapatinib, a dual inhibitor of EGFR and
human epidermal growth factor receptor-2 (HER2) was
studied in patients with EGFR and/or ErbB2 expressing
ACC of the salivary gland [14]. That study, which included
only patients with documented disease progression within
6 months of study entry, observed SD in 15 of 19 patients,
but median PFS duration was only 3.5 months. A few other
targeted agents showed promising efficacy, comparable to
everolimus. EGFR inhibition by cetuximab resulted inFigure 3 Percent changes in maximum standardized uptake values (SU
patients, N = 18).SD in 20 of 23 patients and a median SD duration of
6 months [15]. Recently, a phase II study of sunitinib also
achieved prolonged tumor stabilization, of >6 months, in
62% of patients with documented prior progression [16].
However, objective responses to targeted agents were
rarely observed in patients with advanced ACC. Therefore,
a novel combination of targeted agents could be a reason-
able approach to improve the outcome of systemic treat-
ment of advanced ACC.
Conclusions
Everolimus showed a promising anti-tumor effect in the
treatment of advanced ACC. Trials of novel combinations
of everolimus with other targeted agents are warranted.Vmax) after 2 cycles of everolimus treatment (FDG-PET evaluable
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